Mount Sinai Neuroscientist David Putrino Injects Leg Muscle Mitochondria into Patient's Eyes in Breakthrough Vision Experiment US researchers have conducted a landmark medical experiment by injecting leg muscle mitochondria into the eyes of a 26-year-old blind woman to restore cellular energy. In the field of medical science, researchers are continuously developing novel biomedical techniques to uncover treatments for previously incurable conditions. In daily life, when a remote control or electronic device runs out of power, replacing its depleted battery with a functional one from another device is standard practice. While applying such a concept to the human body might sound extraordinary, scientists are now executing this exact strategy at the microscopic cellular level. In a medical first, a team of researchers led by neuroscientist David Putrino at the Icahn School of Medicine at Mount Sinai in the United States extracted mitochondria from a blind woman's leg muscle and injected them directly into the ocular fluid of both her eyes. Mitochondria function as the cellular powerhouses or biological batteries of the human body, converting nutrients and oxygen into vital biochemical energy. This pioneering clinical attempt aimed to supply immediate metabolic energy to severely damaged retinal cells that had been deprived of oxygen. A New Frontier in Medical Science: Cellular Battery Transplantation Human cellular survival relies heavily on organelle integrity. Mitochondria are specialized intracellular structures responsible for generating adenosine triphosphate, the primary energy currency of the cell. Previous experimental studies had demonstrated that transplanting healthy mitochondria into damaged animal tissues could re-energize failing cells and preserve functional capacity. Building upon these promising animal trials, researchers made the bold decision to evaluate mitochondrial transplantation in a human eye for the very first time. Neuroscientist David Putrino guided the entire clinical research initiative, presenting the findings on the Research Square platform. The human eye is an exceptionally delicate and immunologically specialized organ, meaning the introduction of external cellular components carries significant clinical risks. Nevertheless, the research team undertook this challenge, establishing a landmark milestone in ophthalmic neurology that offers fresh hope for managing previously irreversible optic nerve disorders. From Sudden Trauma to Blindness: The Patient's Medical History The patient at the center of this trial is a 26-year-old woman whose life was dramatically altered following a catastrophic medical event. She suffered a sudden brain hemorrhage, which rapidly escalated into a life-threatening critical condition. Unfortunately, due to distressing circumstances, she could not be admitted to a medical facility for approximately 18 hours after the initial hemorrhage. Upon her delayed arrival at the hospital, medical staff performed emergency surgery to save her life. Although the surgical team succeeded in stabilizing her, the prolonged 18-hour delay in treatment caused severe ischemia, leaving her optic nerves deprived of blood flow and oxygen for a critical duration. This extended oxygen deprivation severely damaged the optic nerves in both eyes, resulting in near-total vision loss. Eight weeks after the emergency intervention, clinical evaluations revealed that her optic nerves had begun to shrink and atrophy. After nearly three months without any meaningful visual recovery under standard care, the medical team decided to explore an unconventional cellular transplant procedure. Why the Leg Muscle Was Chosen: Biopsy and Injection Procedure Comprehensive diagnostic imaging of the patient's eyes revealed that the damage, though extensive, was not complete. The imaging scans demonstrated that a subset of nerve fibers and retinal layers remained intact and viable. Furthermore, brain activity monitoring indicated that minimal visual signals were still managing to travel from the eyes to the brain's visual cortex. These diagnostic findings led neuroscientists to hypothesize that delivering a concentrated boost of functional mitochondria could reactivate these surviving, dormant neural pathways. In any transplantation procedure, donor tissue carries a substantial risk of triggering a destructive host immune response. To eliminate the danger of immune rejection, the medical team utilized the patient's own biological material. Surgeons performed a biopsy on the quadriceps muscle of her thigh, from which lab specialists isolated tens of millions of fresh, viable mitochondria. Using precision techniques, these isolated mitochondria were carefully injected into the fluid of both eyes. The Critical Link Between Optic Nerves and Mitochondrial Energy Retinal ganglion cells, located within the retina at the back of the eye, are essential components of the human visual system. These specialized neurons process visual information captured by the retina and transmit it as electrical impulses through the optic nerve to the brain. According to neuroscientist David Putrino, retinal ganglion cells possess the highest energy demand of any cells within the central nervous system. Their intense metabolic activity makes them completely dependent on mitochondrial energy production. When blood supply and oxygen delivery are cut off during ischemic events, mitochondria are the first intracellular structures to suffer damage, causing energy production to halt and leading to rapid cell death. The primary objective of this transplant was not to resurrect fully dead neurons, but rather to rescue compromised, surviving cells from metabolic failure and provide them with the bioenergetic support needed to maintain function. Experimental Results: Pupil Reactivity and Brain Signals The outcomes of this novel clinical experiment yielded remarkable insights for the medical community. According to the research report, the intraocular mitochondrial injection produced no adverse side effects or dangerous systemic immune reactions, validating the safety of the procedure. Within days following the injection, measurable physiological improvements were observed in the patient's eyes. Prior to the intervention, over a 71-day baseline period, the patient's pupils showed no normal response or contraction when exposed to light. Following the mitochondrial injection, however, the pupils regained a normal light reflex, contracting appropriately in response to illumination. Additionally, neuroimaging sessions conducted on days 3, 44, and 45 post-injection revealed positive electrical activity within the visual cortex of the brain. While the treatment did not restore detailed vision, as the patient could only perceive light rather than form clear images, it demonstrated clear biological responsiveness. The observed pupil reactivity proved to be transient; the left eye exhibited its final normal light response on day 11, while the right eye maintained its response until day 39. Future Implications and the Horizon for Ophthalmic Care Although this unprecedented clinical trial did not achieve full functional vision recovery, it established a key proof of concept: transplanting biological mitochondria into the eye is clinically safe and capable of temporarily restoring cellular reactivity in damaged neural tissue. Neuroscientist David Putrino and his research team believe this work lays a critical foundation for developing mitochondrial therapies aimed at conditions like optic nerve atrophy and glaucoma. Future research efforts will focus on enhancing the longevity and integration of transplanted mitochondria within target cells. By addressing the root cause of cellular energy failure in neurodegenerative conditions, this approach could eventually pave the way for breakthrough treatments that protect and restore sight in millions of patients worldwide. What this means for you Key takeaways and practical impact for readers: • Worldwide and in India: For patients suffering from optic nerve atrophy, glaucoma, or trauma-induced vision loss, this technique offers a novel scientific ray of hope for future sight restoration treatments. • In Medicine and Healthcare: The trial validates that transplanting cellular batteries (mitochondria) is clinically safe, paving the way for revolutionary therapies for currently incurable neurological conditions. Questions & Answers 1. Why did scientists choose the patient's leg muscle for the eye treatment? Using donor tissue carries a high risk of immune rejection. Extracting mitochondria from the patient's own thigh muscle biopsy eliminated any danger of an adverse immune reaction. 2. How did the patient lose her vision? The 26-year-old woman suffered a sudden brain hemorrhage and a delayed treatment of nearly 18 hours, resulting in oxygen deprivation that severely damaged the optic nerves in both eyes. 3. Did the patient regain complete vision after the mitochondrial injection? No, her full sight was not restored. However, her pupils regained a normal light reflex and positive electrical responses were recorded in her brain's visual cortex. 4. Why are mitochondria called the powerhouses of cells? Mitochondria are intracellular organelles that convert nutrients and oxygen into biochemical energy, enabling cells to survive and perform their functional duties. 5. How long did the effects of the mitochondrial injection last? The normal light response persisted until day 11 in the patient's left eye and until day 39 in her right eye before fading. https://trendkia.com/en/health/mount-sinai-men-nyurovaijnanika-david-putrino-ka-anokha-prayoga-paira-ki-mansapeshiyon-se-maitokondriya-nikalakara-mahila-ki-ankho-22490 TrendKia — Har trend, sabse pehle.